New modalities of treatment for hepatocellular carcinoma

  • Arman Karimi Behnagh Student Research Committee, Faculty of Medicine Branch, Iran University of Medical Sciences, Tehran, Iran.
  • Negar Rezaei Department of Epidemiology, School of Public Health, Iran University of Medical Sciences, Tehran, Iran.
  • Mohadeseh Jahannia Student Research Committee, Faculty of Medicine Branch, Iran University of Medical Sciences, Tehran, Iran.
  • Zeynab Noorimotlagh Student Research Committee, Faculty of Medicine Branch, Iran University of Medical Sciences, Tehran, Iran.
  • Ali Kabir Minimally Invasive Surgery Research Center; Iran University of Medical Sciences, Tehran, Iran.

Abstract

Hepatocellular carcinoma (HCC) is the second most common cause of death from cancer worldwide. Managing HCC is difficult. However, there are many treatment options available such as liver transplantation, radiotherapy, different ablative techniques, surgery, trans-arterial chemoembolization (TACE) and systemic therapy. These treatments did not show the promising responses and the recurrence rate is still high. On the other hand, there are some new treatments such as immunotherapy, gene therapy, combination of different therapies, Chinese traditional therapies and new targeted therapies. The aim of this study is to review both the recent changes in the common therapies and newly developed therapies of HCC.Keywords carcinoma, hepatocellular, treatment, combined modality therapy
share this Article by
Published
2017-09-26
How to Cite
KARIMI BEHNAGH, Arman et al. New modalities of treatment for hepatocellular carcinoma. Journal of Contemporary Medical Sciences, [S.l.], v. 3, n. 11, p. 239-252, sep. 2017. ISSN 2413-0516. Available at: <http://www.jocms.org/index.php/jcms/article/view/219>. Date accessed: 23 oct. 2017.